Special Issue "Personalized Vaccine"

Quicklinks

A special issue of Journal of Personalized Medicine (ISSN 2075-4426).

Deadline for manuscript submissions: closed (30 September 2014)

Special Issue Editor

Guest Editor
Prof. Dr. Willem W. Overwijk
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Website: http://faculty.mdanderson.org/Willem_Overwijk/
E-Mail: Woverwijk@mdanderson.org
Interests: cancer immunotherapy; cancer vaccines; tumor immunology; plasmacytoid dendritic cells; interferon

Special Issue Information

Dear Colleagues,

Immunotherapy is delivering on its long-standing promise of powerful, curative cancer therapy. However, it is unclear which therapy is most suited for a given patient, limiting personalized therapy approaches. Mutated genes in an individual’s cancer cells (the mutanome) encode unique peptides (mutatopes) that can be targets for T cells. The recent arrival of next-generation DNA/RNA sequencing and bioinformatics approaches allows, for the first time, the rapid and affordable identification of mutatopes in individual patients. Despite excitement about the use of mutatopes in personalized immunotherapy, there is no experience or consensus on the path to their successful clinical application. Major questions remain, such as whether clinical responses to cytokine therapy, T cell transfer, and CTLA-4 or PD-(L)1 checkpoint blockade are primarily mediated by mutatope-specific reactivity, or whether mutatopes can be effectively targeted with vaccines. Other options for the personalization of immunotherapy are also beginning to emerge, such as screening for PD-L1 expression in tumors and/or stroma of patients receiving PD-(L)1 checkpoint blockade therapy. This special issue of the Journal of Personalized Medicine will present original articles, reviews and opinions on these and other aspects of the exciting new field of personalized immunotherapy.

Prof. Dr. Willem W. Overwijk
Gues Editor

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed Open Access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.

Keywords

  • cancer vaccines
  • personalized medicine
  • t cell epitopes
  • next-generation sequencing
  • epitope prediction
  • checkpoint blockade
  • vaccine adjuvants

Published Papers

No papers have been published in this special issue yet.

Last update: 6 March 2014

J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert